All In MedTech

Device Trial Radar · NCT06772987

NQ TMS for MDD Therapy Using 1 Day x 3 Sessions Protocol for Adult Patient

Safety and Efficacy of an Accelerated, Rectangular Waveform rTMS Protocol in Treatment of Adults With Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

50

Actual

Start

Jan 16, 2025

Primary completion

May 6, 2025

Study completion May 6, 2025

Sponsor

Lead sponsor
NeuroQore Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Makromed Inc.
First posted
Jan 14, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Transcranial Magnetic Stimulation (TMS) Therapy is a non-invasive procedure that uses magnetic pulses to stimulate the cortex (brain) to treat Major Depressive Disorder (MDD). Currently established therapy uses one 19-minute treatment session per day for 5 days per week for 6 weeks, for a total of 30 treatment sessions. The goal of this clinical trial is to evaluate the safety and effectiveness of an accelerated but shortened TMS dosing regimen for adults with MDD aged 22-85. Participants in this study will be subjected to the same 19-minutes treatment session, but three times on the same day, and only for one day. This will greatly reduce the logistical burden of completing the therapy regime.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

  • Accelerated rTMS treatmentDevice

    1 Day x 3 Sessions of 19-minutes rTMS treatment, with 60 minutes rest between sessions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Montgomery-Åsberg Depression Rating Scale (MADRS) ScoreTime frame: From enrollment to final MADRS score assessment within 2 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • LGTC Group

    San Jose, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.